{
    "nct_id": "NCT03363373",
    "official_title": "A Pivotal Phase 2 Trial of Antibody Naxitamab (hu3F8) and Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) in High-Risk Neuroblastoma Patients with Primary Refractory Disease or Incomplete Response to Salvage Treatment in Bone And/or Bone Marrow",
    "inclusion_criteria": "* Diagnosis of neuroblastoma as defined per International Neuroblastoma Response Criteria\n* High-risk neuroblastoma patients with either primary refractory disease or incomplete response to salvage treatment (in both cases including stable disease, minor response and partial response) evaluable in bone and/or bone marrow.\n* Life expectancy â‰¥ 6 months\nHealthy volunteers allowed\nMust have minimum age of 1 Year",
    "exclusion_criteria": "* Any systemic anti-cancer therapy, including chemotherapy or immunotherapy, within 3 weeks before 1st dose of GM-CSF\n* Evaluable neuroblastoma outside bone and bone marrow\n* Existing major organ dysfunction > Grade 2, with the exception of hearing loss, hematological status, kidney and liver function\n* Active life-threatening infection",
    "miscellaneous_criteria": ""
}